Prophylactic Treatment With Atorvastatin for Episodic Migraine.
EpisodicStatinMig. A Multicentre, Triple Blind, Placebo Controlled, Parallel Group Study of Atorvastatin in Episodic Migraine
St. Olavs Hospital
450 participants
May 1, 2024
INTERVENTIONAL
Conditions
Summary
The main objective of this study is to see whether the favorable preventative effect of Atorvastatin 40mg per day in episodic migraine, that was found previously in three smaller randomized controlled cross-over studies, can be confirmed in a larger, multicenter, randomized controlled parallel group study. In addition it will be investigated whether 1) there is an effect of a daily dose of 20mg Atorvastatin, 2) whether the favorable side effect profile, seen in previous studies, can be confirmed, and whether it is even better with the smaller dose, and 3) estimating the cost of Atorvastatin treatment, considering cost of medicine, cost of acute attack medicine, and cost of lost worktime.
Eligibility
Inclusion Criteria8
- Age 18 to 65 years.
- Signed informed consent.
- Episodic migraine with or without aura according to ICHD-3 criteria.
- At inclusion, patients should retrospectively have from 4 to 14 migraine attacks per month during the last 3 months. This frequency must be confirmed in the headache diary before randomisation to treatment.
- Debut of migraine at least one year prior to inclusion based on information in the patient record or by careful examination of previous headache history.
- Start of migraine before 50 years.
- No use of other migraine prophylactics during the study.
- For women of child-bearing potential, there must be no pregnancy or planned pregnancy during the study period, and use of highly effective contraception.
Exclusion Criteria17
- Interval headache not distinguishable from migraine.
- Chronic migraine, chronic tension-type headache, medication overuse headache or other headache occurring on ≥ 15 days/month.
- Pregnancy, planning to get pregnant, inability to use contraceptives, and lactating.
- Clinical information on or signs of cholestasis or decreased hepatic or renal function.
- High degree of comorbidity and/or frailty associated with reduced life expectancy or high likelihood of hospitalization, at the discretion of the investigator.
- Hypersensitivity to statins or previous use of statins.
- History of angioneurotic oedema.
- Use of medicines for migraine prophylaxis less than 4 weeks, or of botulinum toxin less than 16 weeks, prior to start of study.
- Current use of antiviral treatment against hepatitis C.
- Significant psychiatric illness.
- Having tried ≥ 3 prophylactic drugs against migraine during the last 10 years.
- Requiring detoxification from acute medication (triptans, opioids).
- Consistently failing to respond to any acute migraine medication.
- Alcohol or illicit drug dependence.
- Inability to understand study procedures and to comply with them for the entire length of the study.
- Treatment for hypothyroidism.
- Lactose intolerance.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Each tablet will be taken once daily for 84 days.
Each tablet will be taken once daily for 84 days
Each tablet will be taken once daily for 84 days.
Locations(6)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06248671